Ernexa Therapeutics (NASDAQ:ERNA) Rating Lowered to Sell at Wall Street Zen

Ernexa Therapeutics (NASDAQ:ERNA) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

Several other research analysts have also weighed in on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Ernexa Therapeutics in a research note on Tuesday, April 21st. Brookline Capital Markets started coverage on shares of Ernexa Therapeutics in a report on Thursday, May 7th. They set a “buy” rating and a $30.00 target price for the company. Finally, Zacks Research raised shares of Ernexa Therapeutics to a “hold” rating in a report on Monday, May 11th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Ernexa Therapeutics currently has a consensus rating of “Hold” and an average price target of $30.00.

Ernexa Therapeutics Price Performance

Ernexa Therapeutics stock opened at $10.57 on Friday. The firm has a market capitalization of $12.37 million, a PE ratio of -0.40 and a beta of 1.88. The company’s 50-day moving average is $7.09 and its 200-day moving average is $18.33. Ernexa Therapeutics has a fifty-two week low of $3.18 and a fifty-two week high of $91.54.

Ernexa Therapeutics (NASDAQ:ERNA) last released its quarterly earnings data on Monday, May 11th. The company reported ($6.95) earnings per share for the quarter, missing the consensus estimate of ($1.95) by ($5.00). As a group, analysts expect that Ernexa Therapeutics will post -9.38 EPS for the current year.

Institutional Trading of Ernexa Therapeutics

A hedge fund recently bought a new stake in Ernexa Therapeutics stock. Susquehanna International Group LLP bought a new position in shares of Ernexa Therapeutics Inc. (NASDAQ:ERNA) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned 0.39% of Ernexa Therapeutics as of its most recent filing with the SEC. Institutional investors and hedge funds own 70.55% of the company’s stock.

About Ernexa Therapeutics

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.